Ferring study highlights impact of nocturia
5 September 2011 00:00 in Pharmaceutical Company Product News
Ferring Pharmaceuticals has highlighted the findings of a new study that underlines the impact nocturia can have on the quality of life of patients.
The condition, which involves waking several times during the night in order to pass urine, was shown during the study to have a similar impact on mental and physical wellbeing as chronic conditions such as hypertension, diabetes and arthritis.
Among the debilitating conditions associated with the disease are sleep disturbance, depression, disrupted endocrine and immune functioning, reduced health and increased mortality.
According to the report, this shows the need for greater consideration of the impact of a disease that is often passed off as a natural part of the ageing process.
Dr Varant Kupelian of New England Research Institutes said: "This data sheds light on the real impact nocturia can have on the mental wellbeing and overall quality of life of patients with this under-reported condition."
Last week, Ferring published data from a clinical study of Firmagon, its approved prostate cancer drug, which offered new evidence of the product's efficacy.
Other news stories from 05/09/2011
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
